Oncolytics Biotech (ONCY) Current Assets (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Current Assets of $6.8 million for Q4 2025, down 49.35% year-over-year from $13.5 million in Q4 2024, and down 32.97% quarter-over-quarter from $10.2 million in Q3 2025.
Oncolytics Biotech (ONCY) Current Assets (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Current Assets for 17 consecutive years, with $6.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets fell 49.35% year-over-year to $6.8 million; the TTM figure through Dec 2025 stood at $6.8 million (down 49.35% YoY), while the FY2025 annual figure was $6.8 million, down 44.97% from the prior year.
- Current Assets declined to $6.8 million in Q4 2025 per ONCY's latest filing, from $10.2 million in the prior quarter.
- Across five years, Current Assets topped out at $45.1 million in Q2 2021 and bottomed at $6.8 million in Q4 2025.
- Historically, Current Assets has averaged $25.8 million across 5 years, with a median of $25.8 million in 2022.
- Annual changes were most pronounced in 2021 — Current Assets soared 37.66% — and 2024, when it sank 51.81%.
- Oncolytics Biotech's Current Assets stood at $35.6 million in 2021, then declined by 26.21% to $26.3 million in 2022, then increased by 6.66% to $28.0 million in 2023, then tumbled by 51.81% to $13.5 million in 2024, then tumbled by 49.35% to $6.8 million in 2025.
- Business Quant data shows ONCY's Current Assets at $6.8 million in Q4 2025, $10.2 million in Q3 2025, and $13.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Oncolytics Biotech | 96.23 Mn | 96.23 Mn | - | 7.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.07 Mn |
| Dec 31, 2025 | 6.84 Mn |
| Sep 30, 2025 | 10.21 Mn |
| Jun 30, 2025 | 13.64 Mn |
| Mar 31, 2025 | 12.88 Mn |
| Dec 31, 2024 | 13.51 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 22.40 Mn |
| Mar 31, 2024 | 24.77 Mn |
| Dec 31, 2023 | 28.04 Mn |
| Sep 30, 2023 | 33.82 Mn |
| Jun 30, 2023 | 23.07 Mn |
| Mar 31, 2023 | 25.34 Mn |
| Dec 31, 2022 | 26.29 Mn |
| Sep 30, 2022 | 29.29 Mn |
| Jun 30, 2022 | 30.91 Mn |
| Mar 31, 2022 | 34.37 Mn |
| Dec 31, 2021 | 35.62 Mn |
| Sep 30, 2021 | 40.99 Mn |
| Jun 30, 2021 | 45.10 Mn |